Thymalin has older regional human studies, but the evidence is dated, difficult to generalise and low certainty by modern standards. Claims about lifespan extension or broad anti-ageing benefit are not established.
Still uncertain: Reliable lifespan extension, modern replicated clinical benefit, contemporary long-term safety or a validated anti-ageing regimen.
By confirming your subscription, you agree to receive occasional WhichPeps Evidence Updates. Kit processes the signup and email delivery for WhichPeps. Privacy. Unsubscribe anytime.
What does the evidence mean in simple terms? table
What is it?
Thymic peptide preparation/extract
Entity type
Peptide preparation / extract
Research focus
Immunology, ageing and oncology-adjunct research
Human evidence
Older regional human studies report immune-marker effects and long-term gerontology/longevity signals, but the methods and independent replication do not support high contemporary certainty.
Regulatory status
No FDA/EMA-approved Thymalin medicine identified.
Main limitations
Reliable lifespan extension, modern replicated clinical benefit, contemporary long-term safety or a validated anti-ageing regimen.
Safety
Modern standardized safety data and product equivalence are limited.
Evidence reviewed
2026-09-18
i
Older regional human studies report immune-marker effects and long-term gerontology/longevity signals, but the methods and independent replication do not support high contemporary certainty.
Outcome-level evidence
Evidence is not one score.
Each record below answers a narrower question about an outcome, population or context. Evidence status and the study finding are shown separately so strong evidence is not mistaken for a positive effect.
Thymalin added to standard treatment in non-specific pulmonary disease
1989 · Small controlled clinical study · n=35
Thymalin was associated with normalization of lymphocyte count and OKT-4+/OKT-8+ subpopulations; little effect was reported on several other immune measures.
Modern standardized safety data and product equivalence are limited.
Technical details
Mechanism / biologyHistorical thymic peptide preparation proposed to modulate immune/endocrine ageing pathways; composition/standardisation differs from single defined peptides.
Route / formulation boundaryHistorical preparations may not be compositionally equivalent to current commercial vials.
Identity / data-quality noteTreat large longevity claims as low-certainty due older regional methods and limited independent replication.
Study / label regimen evidenceVerified context-specific human IM study exposure added. A severe-COVID retrospective study used 10 mg intramuscularly once daily for 5 days alongside basic treatment. This is context-specific study exposure, not a general regimen, and product standardisation/equivalence remains uncertain.
WhichPeps does not rely on a single headline study when the evidence base is broader. Primary research, registries, regulators and supporting records are kept distinct.
2structured study records
3outcome records
6linked source records
How to read these counts: they show evidence coverage, not evidence strength. One large, well-designed study can be more informative than several weak or indirect records.
Show supporting and discovery sources
Study pages above contain the records used for public evidence summaries. The links below include supporting, regulatory and literature-discovery sources; a registry or search result is not treated as proof of benefit.
Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.
